# Strategic Timing of Antiretroviral Treatment

> **NCT00867048** · PHASE4 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 4688 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** All licensed antiretroviral medications

## Key facts

- **NCT ID:** NCT00867048
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-15
- **Primary completion:** 2022-07-27
- **Final completion:** 2022-07-27
- **Target enrollment:** 4688 (ACTUAL)
- **Last updated:** 2024-03-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00867048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00867048, "Strategic Timing of Antiretroviral Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00867048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*